Derivation of clinical -grade mesenchymal stromal cells from umbilical cord under chemically de fined culture condition-platform for future clinical application
单位：[1]Key Laboratory of Biomedical Information Engineering of the Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China[2]Interventional Department, the First Afiliated Hospital of Baotou Medical Collge, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China[3]Department of Technology, Stem Cell Medicine Engineering & Technology Research Center of Inner Mongolia, Huhhot, Inner Mongolia, China[4]Department of pharmacy, Beiing Friendship Hospital, Capital Medical University, Beijing, China医技科室药学部首都医科大学附属北京友谊医院
The use of animal serum in culture medium brings safety concerns and batch -to -batch variability, and thus may restrict the clinical use of ex vivo expanded mesenchymal stromal cells (MSCs). Clinically compliant MSCs should be developed in adherence to serum -free, xeno-free and chemically de fined medium (S&XFM-CD). In this study, we develop a S&XFM-CD by replacing all serum components with synthetic alternatives for the deri- vation of clinical -grade umbilical cord -derived MSCs (UCMSCs). The critical aspects including characterization, safety concerns, potency and exogenous factors contamination risk of UCMSCs in S&XFM-CD are compared with serum -containing medium (SCM). UCMSCs in S&XFM-CD retain fibroblastic -like morphology and immu- nophenotype of MSCs, and exhibit superior clone ef ficiency, proliferation capacity, and osteogenic and chon- drogenic differentiation potential compared with SCM. Moreover, UCMSCs in S&XFM-CD retain similar immunosuppressive potential, and exhibit superior secretion levels of bFGF, PDGF-BB and IGF-1 compared with SCM. In addition, UCMSCs in S&XFM-CD do not undergo transformation, preserve the normal karyotypes and genomic stability, and are less prone to senescence process after long-term in vitro culture, which con- forms to the current guidance of international and national evaluation standard. The S&XFM-CD developed here may serve as a GMP-grade production platform of UCMSCs for future clinical application. ? 2020 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81860157, 81960252]; Natural Science Foundation of Inner Mongolia [2019MS08047]
第一作者单位：[1]Key Laboratory of Biomedical Information Engineering of the Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China[2]Interventional Department, the First Afiliated Hospital of Baotou Medical Collge, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China[3]Department of Technology, Stem Cell Medicine Engineering & Technology Research Center of Inner Mongolia, Huhhot, Inner Mongolia, China
通讯作者：
通讯机构：[1]Key Laboratory of Biomedical Information Engineering of the Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China[*1]Key Laboratory of Biomedical Information Engi- neering of the Ministry of Education,School of Life Science and Technology,Xi'an Jiao- tong University,Xi'an,710049P.R.China.
推荐引用方式(GB/T 7714)：
Wu Xiaoyun,Ma Zhijie,Wu Daocheng.Derivation of clinical -grade mesenchymal stromal cells from umbilical cord under chemically de fined culture condition-platform for future clinical application[J].CYTOTHERAPY.2020,22(7):377-387.doi:10.1016/j.jcyt.2020.03.431.
APA：
Wu, Xiaoyun,Ma, Zhijie&Wu, Daocheng.(2020).Derivation of clinical -grade mesenchymal stromal cells from umbilical cord under chemically de fined culture condition-platform for future clinical application.CYTOTHERAPY,22,(7)
MLA：
Wu, Xiaoyun,et al."Derivation of clinical -grade mesenchymal stromal cells from umbilical cord under chemically de fined culture condition-platform for future clinical application".CYTOTHERAPY 22..7(2020):377-387
